Last reviewed · How we verify
Nepafenac and lubricant
Nepafenac and lubricant, marketed by Instituto de Oftalmología Fundación Conde de Valenciana, is a post-surgical ophthalmic treatment with a key composition patent expiring in 2028. The drug's market position is bolstered by its unique combination of anti-inflammatory and lubricating properties, which differentiates it from other ophthalmic treatments. The primary risk is the potential for increased competition following the 2028 patent expiry.
At a glance
| Generic name | Nepafenac and lubricant |
|---|---|
| Sponsor | Instituto de Oftalmología Fundación Conde de Valenciana |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Comparative Analysis of the Effectiveness of Nepafenac Combined With a Lubricant Versus a Lubricant Alone in the Treatment of Epiphora Associated With Lacrimal Punctum Stenosis (PHASE4)
- Effect of Topical Nepafenac in Macular Thickening Related to Pan-retinal Photocoagulation (PHASE2)
- CHED - Congenital Hereditary Endothelial Dystrophy: New Paradigm Shift in Therapy Using Topical Eye Drops (PHASE2)
- Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections (NA)
- Effect of Topical Nepafenac 0.1% on Pain Related to Intravitreal Injections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: